The Single Dose Pharmacokinetics of Two and Proof of Efficacy of One New Etoricoxib Gel Formulation in Participants With Osteoarthritis (MK-0663-168)

Exclusion Criteria

• •Has a concurrent medical/arthritic disease;
• •History of acute ligamentous or meniscal injury of the study joint within the previous 2 years or arthroscopy of the affected knee within 6 months prior to study entry;
• •Is a candidate for imminent joint replacement;
• •Has clinical or laboratory evidence of significant renal, gastrointestinal, pulmonary, hepatic, endocrine, neurological (apart from migraine), or other systemic disease that in the opinion of the investigator contraindicates the use of etoricoxib;
• •Has congestive heart failure with symptoms that occur at rest or minimal activity;
• •Has unstable angina that occurs at rest or with minimal activity;
• •Has uncontrolled hypertension (sitting diastolic blood pressure \>95 mm Hg, or sitting systolic blood pressure \>165 mm Hg);
• •Has a history of stroke or transient ischemic attack (TIA) within the previous 6 months;
• •Has a history of hepatitis/hepatic disease that has been active within the previous 2 years;
• •Has a history of neoplastic disease;
• •Is currently a user (including "recreational use") of any illicit drugs, or has a history of drug or alcohol abuse within the past 5 years;
• •Is allergic of has hypersensitivity to aspirin, ibuprofen, rofecoxib, celecoxib, valdecoxib, other NSAIDs, acetaminophen, or sulfa drugs;
• •Has used intravenous, intramuscular, or oral corticosteroids within 1 month of study entry;
• •Has used glucosamine and/or chondroitin sulfate for \<6 months prior to study start;
• •Has used intra-articular steroids, HYALGAN™ (sodium hyaluronate, Sanofi Pharmaceuticals), or SYNVISC™ (hylan G-F 20, Wyeth-Ayerst Pharmaceuticals) to the study joint within 3 months of entry into the study or intra-articular steroids, HYALGAN™, or SYNVISC™ to any other joint within 1 month of study entry;
• •Has used topical, oral or systemic analgesic medications within 2 weeks of study entry and for the duration of the study;
• •Requires treatment with warfarin, heparin, high-dose aspirin (\>325 mg), or digoxin;
• •Has used Arcoxia® within 2 weeks of study entry.